Newer oral medicines for patients with T2DM such as the DPP4 (dipeptidyl peptidase-4) and SGLT2 (sodium/glucose cotransporter 2) inhibitors have also been proposed (Naidoo et al., 2014; Imprialos et al., 2017; Bailey and Day, 2019; Li et al., 2019). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.